Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Sanofi-aventis to develop asthma and COPD treatments

Sanofi-aventis to develop asthma and COPD treatments

18th July 2008

Sanofi-aventis has signed a three-year agreement with John Hopkins University to develop treatments for respiratory diseases.

The partnership with the Division of Allergy and Clinical Immunology (ACI) at the university will investigate more specifically immuno-allergic diseases, chronic obstructive pulmonary disease and severe asthma.

Collaboration between the two centres will include the selection of biomakers and decisions relating to the design of clinical studies.

“For each research theme, John Hopkins ACI and sanofi-aventis will work on new target identification, assay development and compound screening,” said sanofi-aventis.

Dr Marc Cluzel, senior vice president of research and development for the company, said he is looking forward to working with the university.

Severe asthma is defined as patients who do not respond well to such therapies as high dose inhaled steroids. The company said more research is needed into the main path-physiological mechanisms of the condition.

Sanofi-aventis has over 18,000 research staff worldwide in 25 centres.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.